Compare New York Times Co (NYT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Vertex Pharmaceuticals Incorporated — how do they compare? New York Times Co trades at $75.8 (market cap $12.29B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.9× New York Times Co's market cap, and New York Times Co pays a 1.21% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NYT | VRTX | |
|---|---|---|
Market Cap | $12.29B | $121.95B |
Sector | Media | Health |
52-Week High | $85.86 | $529.59 |
52-Week Low | $51.43 | $366.54 |
Enterprise Value | $11.68B | $116.69B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYSE: NYT) trades at $74.69, down 1.63% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $2.82 billion in 2025, with net income margin expanding to 12.17%. The stock is supported by strong cash flow from operations of $584 million and a consensus analyst price target of $78.00. Recent news includes the company's motion to quash subpoenas related to reporting on Air Force One, highlighting ongoing legal and press freedom challenges.
Outlook remains positive with consistent earnings growth and a defensive profile amid geopolitical tensions, but risks include regulatory pressures and competitive threats to digital subscriptions. The stock offers a dividend yield with the next payment scheduled for July 23, 2026. Institutional sentiment is mixed with a majority hold rating, suggesting cautious optimism for near-term appreciation toward the price target.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
